Endexx Corporation (EDXC) Contract with Impulse Health to Target Multibillion-Dollar Automation Market

According to Research and Markets, the global pharmacy automation market is expected to reach $9.55 billion by 2022. Research and Markets predicts that retail automation worldwide is expected to reach $18.99 billion by 2023. There is a growing global trend toward utilizing automation in numerous industries, especially in retail and pharmacies, for the purpose of reducing costs and errors and increasing safety measures.

With this collaboration, Endexx will partner with Impulse Health to offer a new customer focused solution to over 20,000 retail and pharmacy locations nationwide utilizing Endexx’s AutoSpense™ industrial-grade automated inventory control and dispensing solutions. Now, customers will be able to automate the retail process and have access to inventory and be able to pick up products as well as prescriptions after hours. In addition, the retail stores and pharmacies will have the ability to provide additional value-added service, increase productivity and sales, improve security and reduce operating costs.

Dustin Sullivan, VP Business Development with Impulse Health, comments, “We are excited to bring AutoSpense™ to the marketplace. This creates a new standard for customer access to restricted or regulated products. AutoSpense™ delivers a new solution for our retail partners that protects consumer privacy, improves tracking of regulated products and reduces overall product shrink.”

“Impulse Health has a highly talented and successful management team with a strong depth of experience in both pharmacy and retail, and we see a complementary fit for their products within our AutoSpense™ solution,” said Todd Davis, CEO of Endexx. “This collaboration represents a significant milestone in advancing our technology forward.  This contract will significantly expand our footprint nationwide in both technology and points of distribution for our nutraceutical product line.”

About Endexx

Endexx, with its collaborative partners and consultants, develops and distributes two consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids. Phyto-Bites®, is its CBD-infused soft chews for dogs. The dog treats are formulated to promote health and support the reduction of separation anxiety, pain and inflammation. The company also has two technology products and services that launched in 2014 — the M3hub and the Autospense™. Both products provide essential solutions to promote regulatory compliance and full accountability through “seed to sale” inventory management and, an “End of Sale” technology integration. Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to eventual federal mandates. The Autospense™ is a commercial grade inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailers, while enhancing their service quality by reducing transaction time for customers.

Websites include: www.cbdunlimited.com, www.endexx.com, www.phytobites.com, www.m3hub.com, www.holisticearthremedies.com.

Safe Harbor Notice

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.